New dosing regimen to boost uptake of Japanese encephalitis vaccine

France’s Valneva (Euronext: VLA) has won US FDA approval for an accelerated dosing regimen of its Japanese encephalitis (JE) vaccine, Ixiaro.

Ixiaro is the only vaccine approved in the USA for protection against Japanese encephalitis – a rare, serious disease endemic to 24 countries in Asia and parts of the Western Pacific.

The accelerated dosing regimen means that adults aged 18 to 65 years may now receive two separate doses of the therapy seven days apart, rather than 28 days apart.